Adlai Nortye names Christopher Liu head of investor and public relations
The clinical-stage oncology company said Liu, a former equity research analyst, will join as of September 30, 2026 to lead its IR and PR efforts.
SEC filing
Latest
3 stories
Yesterday
Monday, August 3
Adlai Nortye clears Australian regulatory steps for AN4035 phase I trial
The company submitted a trial notification and won ethics approval to test its pan-RAS(ON) ADC AN4035 in Australia, with dosing expected in the second half of 2026.
SEC filing
Thursday, July 16
Adlai Nortye doses first patient in weekly-dosing arm of AN9025 Phase 1 trial
The company said both once-weekly and once-daily dosing arms of its pan-RAS(ON) inhibitor study are now enrolling, with early data expected in 1H27.
SEC filing